The European Commission (EC) has approved the cancer cure drug Ogivri that Biocon co-developed with its US-based partner Mylan, said the Indian biotech major on December 18.

"The EC has granted marketing authorisation for our cancer cure drug Ogivri, developed jointly with our partner Mylan," said the city-based firm in a statement. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had earlier recommended approval of the drug as a biosimilar Trastuzumab to Roche's Herceptin on October 18. The drug can be prescribed as monotherapy or in combination with other medicines depending upon the diagnosis under professional supervision.